Biopharma Roivant's Q2 income from operations misses

Reuters

2025/11/10

Biopharma Roivant's <a href="https://laohu8.com/S/QTWO">Q2</a> income from operations misses

Overview

Roivant Q2 revenue declines, missing analyst expectations for income from operations
Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability
Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo

Outlook

Roivant plans NDA filing for brepocitinib in DM in H1 2026
Immunovant expects TED study results in H1 2026

Result Drivers

Research and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue		$1.57 mln
Q2 EPS		-$0.17
Q2 Net Income		-$166.04 mln
Q2 Income From Operations	Miss	-$306.23 mln	-$278.40 mln (7 Analysts)
Q2 Operating Expenses		$307.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62

Press Release: ID:nGNX9SlRMC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582875586"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582875586\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582875586?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582875586","market":"nz","top_or_hot":-1,"title":"Biopharma Roivant's Q2 income from operations misses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Roivant's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> income from operations misses</title></head><body><p><span>Overview</span></p><ul><li><p>Roivant Q2 revenue declines, missing analyst expectations for income from operations</p></li><li><p>Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability</p></li><li><p>Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans NDA filing for brepocitinib in DM in H1 2026</p></li><li><p>Immunovant expects TED study results in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.57 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$166.04 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$306.23 mln</p></td><td><p>-$278.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$307.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62</p></li></ul><p>Press Release: <span>ID:nGNX9SlRMC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma Roivant's Q2 income from operations misses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma Roivant's Q2 income from operations misses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma Roivant's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> income from operations misses</title></head><body><p><span>Overview</span></p><ul><li><p>Roivant Q2 revenue declines, missing analyst expectations for income from operations</p></li><li><p>Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability</p></li><li><p>Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans NDA filing for brepocitinib in DM in H1 2026</p></li><li><p>Immunovant expects TED study results in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.57 mln</p></td><td></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$166.04 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$306.23 mln</p></td><td><p>-$278.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$307.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62</p></li></ul><p>Press Release: <span>ID:nGNX9SlRMC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D9:1","article_id":"2582875586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582875586","pubTimestamp":1762776864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma Roivant's Q2 income from operations missesOverviewRoivant Q2 revenue declines, missing analyst expectations for income from operationsCompany maintains strong cash position of $4.4 bln, supp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ROIV":"Roivant Sciences Ltd.","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","IMVT":"Immunovant, Inc."},"translate_title":"生物制药Roivant第二季度运营收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":0.9,"ROIV":0.9},"content_text":"Biopharma Roivant's Q2 income from operations missesOverviewRoivant Q2 revenue declines, missing analyst expectations for income from operationsCompany maintains strong cash position of $4.4 bln, supporting cash runway into profitabilityBrepocitinib Phase 3 study in dermatomyositis shows significant improvement over placeboOutlookRoivant plans NDA filing for brepocitinib in DM in H1 2026Immunovant expects TED study results in H1 2026Result DriversResearch and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ2 Revenue$1.57 mlnQ2 EPS-$0.17Q2 Net Income-$166.04 mlnQ2 Income From OperationsMiss-$306.23 mln-$278.40 mln (7 Analysts)Q2 Operating Expenses$307.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62Press Release: ID:nGNX9SlRMCFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}